Theusus Pharmaceuticals

Theseus is a biopharmaceutical company dedicated to improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theusus Pharmaceuticals is developing next-generation pan-variant kit inhibitors for the treatment of refractory gastrointestinal stromal tumors (GIST). The company's pipeline also includes a selective EGFR inhibitor designed to overcome c797s-mediated resistance to osimertinib in first-line or advanced non-small cell lung cancer patients. The company is also developing a third kinase candidate target for undisclosed indications.